Please provide your email address to receive an email when new articles are posted on . It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as ...

May 19, 2011 (Charlottesville, Virginia) — Whereas statins appeared to halt atherosclerosis, ezetimibe (Zetia, Merck/Schering-Plough) was associated with an increase in plaque volume in peripheral ...

In this study, after a six- to eight-week washout period, patients with mixed hyperlipidemiaLDL cholesterol between 130 and 220 mg/dL (between 100 and 180 mg/dL for type 2 diabetics) and triglycerides ...

Ezetimibe is a nonstatin low-density lipoprotein cholesterol-lowering small molecule drug. Ezetimibe is the only currently FDA-approved approved member of the of intestinal cholesterol reuptake ...

(HealthDay)—Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to ...

A recent simulation study published in the journal Scientific Reports analyzed representative data of over two million outpatients in Germany, in which the researchers reported that a combination of ...

What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to ...

The US Food and Drug Administration has declined to extend the indication for the cholesterol-lowering drug ezetimibe to include cardiovascular event reduction, the manufacturer has announced. Merck ...

A combination of simvastatin and ezetimibe (Vytorin) lowered cholesterol better than simvastatin alone, but it had no effect on arterial plaque in a major clinical trial. As a result, cardiologists ...

Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of ...

Moderate-intensity statin with ezetimibe combination therapy was confirmed to be effective on low-density lipoprotein cholesterol (LDL-C) reduction in patients at very high risk of atherosclerotic ...

(HealthDay News) — Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to ...